The official Drugs@FDA record for NDA 021332 documents SYMLIN (pramlintide acetate) approval on 03/16/2005 as a Type 1 new molecular entity, with all three marketed strengths (SymlinPen presentations) now listed as Discontinued. The record's supplement history traces the drug's regulatory life from 2005 approval through the 2019 final labeling supplement.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.